Armed with promis­ing alope­cia PhII, Con­cert edges for­ward with mod­i­fied JAK in­hibitor — but safe­ty will still be key

Con­cert Phar­ma has scored a fresh round of pos­i­tive Phase II da­ta for its JAK in­hibitor amid an on­go­ing ri­val­ry with Pfiz­er, paving the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.